Rapid Communication

Loss of fragile histidine triad protein expression in inflammatory bowel disease

Chun-Mei Xu, Chuan-Hu Qiao

Chun-Mei Xu, Chuan-Hu Qiao, Department of Gastroenterology, Xiangfan No.1 Hospital, 75 Jiefang Road, Xiangfan 441000, Hubei Province, China

Supported by grant from Wuhan Municipal Government Science and Technology Department No. 301121017

Correspondence to: Chuan-Hu Qiao, Department of Gastroenterology, Xiangfan No.1 Hospital, 75 Jiefang Road, Xiangfan 441000, Hubei Province, China. chunmei200311@tom.com

Telephone: +86-13487159389

Received: 2005-11-26 Accepted: 2006-10-21

Abstract

AIM: To investigate the expression of fragile histidine triad (FHIT) protein in 64 patients with ulcerative colitis (UC) and Crohn’s disease (CD), and its relation with clinicopathological data.

METHODS: Rabbit-anti-FHIT antibody was used to detect FHIT protein expression in 64 formalin-fixed, paraffin-embedded tissue specimens of inflammatory bowel disease (IBD) by citrate-microwave-streptavidin (SP)-HRP immunohistochemical method.

RESULTS: The positive FHIT protein expression was 22.79% ± 16.16%, 42.14% ± 16.82% in active and remittent phases of UC, 36.07% ± 19.23% in CD, and 57.05% ± 8.86% in normal colon mucosa. Statistically significant differences in FHIT protein expression were observed between the active and remittent phases of UC, between the active phase of UC and normal colon mucosa, as well as between the remittent phase of UC and normal colon mucosa, and between CD and normal colon mucosa.

CONCLUSION: Our results show that FHIT protein expression is completely absent or reduced in IBD, suggesting that the FHIT gene might be associated with the oncogenesis and progression of IBD, an early event from inflammatory conditions to carcinoma in IBD.

© 2006 The WJG Press. All rights reserved.

Key words: Fragile histidine triad protein expression; Ulcerative colitis; Crohn’s disease; Inflammatory bowel disease

Xu CM, Qiao CH. Loss of fragile histidine triad protein expression in inflammatory bowel disease. World J Gastroenterol 2006; 12(45): 7355-7360

http://www.wjgnet.com/1007-9327/12/7355.asp

INTRODUCTION

Inflammatory bowel disease (IBD) is a collection of chronic idiopathic inflammatory disorders of the intestine and/or colon, including two independent diseases: ulcerative colitis (UC) and Crohn’s disease (CD)[2-7]. Up to now, the complex etiology and pathogenesis of IBD are not known with certainty, but the growing theories suggest that many factors such as environment, genetic alteration, uncontrolled immune system, etc, can result in chronic gut inflammation[2-7]. However, none of the theories provides a sufficient explanation of either disease, indicating that their etiology is multifactorial. It has been well established that colorectal carcinoma is the most serious complication of patients with long-standing IBD who have an increased risk of developing colorectal carcinoma[8-11]. The cumulative risk of carcinoma in IBD patients is estimated to be 10-20 times greater in the small bowel and 4-20 times greater in the large bowel than that in the small and large bowel of general population. The mean duration of colitis before cancer diagnosis ranges 17-20 years. Dysplasia occurring in IBD constitutes a precursor stage of carcinoma[12,13]. Patients with IBD are characterized by recurrent acute mucosa inflammation, mucosal ulceration, epithelial necrosis and regeneration, all of which may result in DNA damage, genetic alterations including enhanced microsatellite instability of mucosa, activation of oncogene, inactivation of tumor suppressor gene, increasing susceptibility to mutagenesis and subsequent neoplastic transformation[6-18].

The fragile histidine triad (FHIT) gene was discovered at human chromosome 3p14.2 in 1996 by Ohta et al[19] using the exon trapping method, and has been identified as a candidate tumor-suppressor gene. This gene not only spans the translocation breakpoint of familial renal-cell carcinoma, but also encompasses the most active common human chromosomal fragile region, FRA3B[19,20]. The approximately 1-megabase FHIT gene includes 10 exons, encoding 1.1Kb mRNA transcript, 16.8 kDa, and 147 amino acid proteins[21]. FHIT protein is a member of the recently discovered histidine triad (HIT) family of nucleotide-binding proteins with a high specific hydrolysing activity for diadenosine 5', 5'''-P1, Pn-polyphosphate (ApnA), where n = 3-6. The FHIT protein encoded by the FHIT gene can hydrolyze APnA...
and AP4A to ADP and AMP\cite{20,22}. It was reported that the FHIT gene can facilitate deletions and aberrant transcripts and may play an important role in a variety of human malignancies\cite{23-26}, including cancers of lung\cite{27}, breast\cite{28}, pancreas\cite{29}, urinary bladder\cite{30}, head and neck\cite{31} and gastrointestinal carcinomas\cite{32-34}.

Since the role of FHIT aberrations is unclear and results from different investigators are contradictory, the present study was to evaluate the expression of FHIT protein in patients with IBD and its relation with clinicopathological data.

**MATERIALS AND METHODS**

**Patients**

Biopsy specimens from 64 IBD patients including 47 UC and 17 CD patients were obtained from several hospitals in Hubei Province from 1990 to 2005. All the patients were diagnosed in the light of clinical, endoscopic, histological and radiological criteria. All IBD patients underwent sigmoidoscopy or colonoscopy for routine clinical evaluation. Mucosal inflammation in active UC was classified as mild inflammation: mild-to-moderate small round-cell infiltration with formation of a few crypt abscesses in the lamina propria; severe inflammation: severe small round-cell infiltration with multiple crypt abscesses and partial granulation in the lamina propria. Remission was defined histologically as areas with branched or regenerated irregular crypts without acute inflammation but with chronic mild inflammation. Ten apparently normal colonic tissue sections were obtained. The mean age of 47 patients including 34 men and 13 women at the onset of UC was 36.9 years (averaged 13.4 years). The mean age of the remaining 17 patients including 10 men and 7 women at the onset of CD was 38.0 years (averaged 13.9 years).

**Reagents and antibodies**

Rabbit anti-FHIT polyclonal antibody (Zymed Company, USA) was purchased from Beijing Zhongshan Biological Technology Co., Ltd. Immunohistochemical staining S-P kit (Zemed MAXIM, USA) was purchased from Maixin Co., LTD.

**Methods**

All the biopsy specimens were fixed in 10% buffered formalin and embedded in paraffin wax. Four-μM thick sections were routinely prepared and stained with haematoxylin and eosin, while other sections were prepared with immunohistochemical SP staining method. In brief, the tissue sections were routinely dewaxed in xylene, dehydrated at graded concentrations of alcohol, and treated with 3% hydrogen peroxide for 10 min to block the endogenous peroxidase. The sections were immersed in citrate buffer (5 mmol/L sodium citrate, pH = 6.0), heated in a microwave oven for 2 min to enhance antigen retrieval, and then placed at room temperature for 10 min. The sections were blocked with normal goat serum for 15 min and incubated with rabbit anti-FHIT polyclonal antibody (1:100 dilution) overnight at 4°C. After washed three times in PBS, the binding of antibodies to their antigenic sites in the tissue sections was further amplified with biotinylated goat anti-rabbit antibody followed by reaction with streptavidin-biotin peroxidase. Antibody localization was detected with diaminobenzidine as a chromogen substrate. Sections prepared by substituting PBS for the primary antibody served as a negative control. The freshly prepared substrate DAB was added for color development. The sections were washed in distilled water and counterstained with haematoxylin and mounted for examination.

**Determination of FHIT expression**

Negatively expressed FHIT manifested as blue-stained nuclei while positively expressed FHIT manifested as brown or dark brown cytoplasm and/or cell membrane mainly in epithelial tissues. Expressions of these target proteins were semi-quantitated with automatic image analyzer (Nikon, Japan) and HPIAS-2000 image analyzing program, in which the average value of positive cells in 10 randomly selected high power fields (× 400) for each section was used for the comparison of the target protein expressions.

**Statistical analysis**

Quantitative variables were expressed as mean ± SD. Statistical comparisons between groups were made by one-way ANOVA. Differences in results between the two groups were tested with t test. P < 0.05 was considered statistically significant. All analyses were performed using the SPSS version 14.0.

**RESULTS**

The classification of IBD patients according to their clinicopathological characteristics and their association with FHIT protein expression are shown in Tables 1 and 2.

The pattern of FHIT protein expression was confined to the epithelial cells, especially cytoplasm. As shown in Figure 1A-1D, FHIT protein expression was unequivocal in normal colonic tissue and reduced or absent in UC and CD. The positive FHIT expression was 22.79% ± 16.16%, 42.14% ± 16.82%, respectively in active and remittent phases of UC, 36.07% ± 19.23% in CD, and 57.05% ± 8.86% in normal colon mucosa. Statistically significant differences in FHIT protein expression were observed between the active and remittent phases of UC (P < 0.05), between the active phase of UC and normal colon mucosa (P < 0.01), as well as, between the remittent phase of UC and normal colon mucosa (P < 0.01), and between CD and normal colon mucosa (P < 0.01).

**DISCUSSION**

Recent studies showed that tumourigenesis is related to inflammatory conditions, such as IBD and pancreatitis, and inflammation has been considered as precancerous, but the possible link between inflammation and tumourigenes is still unclear\cite{14,35,38}. Chronic inflammatory conditions such as UC are thought as the risk factor for some carcinomas, the incidence of colon carcinoma in UC is estimated to be 5-7 times greater than what we have expected,
Table 1  Clinicopathological data of patients with inflammatory bowel disease

| Patient No. | Sex | Age (yr) | Disease extension |
|-------------|-----|----------|-------------------|
| 1           | M   | 54       | Terminal ileum    |
| 2           | F   | 20       | Ileocolonic       |
| 3           | M   | 40       | Pancolitis        |
| 4           | M   | 70       | Right-sided       |
| 5           | F   | 62       | Ileocolonic       |
| 6           | M   | 27       | Terminal ileum    |
| 7           | M   | 26       | Terminal ileum    |
| 8           | F   | 34       | Ileocolonic       |
| 9           | M   | 51       | Pancolitis        |
| 10          | M   | 41       | Pancolitis        |
| 11          | M   | 29       | Right-sided       |
| 12          | F   | 25       | Left-sided        |
| 13          | M   | 35       | Terminal ileum    |
| 14          | F   | 38       | Ileocolonic       |
| 15          | F   | 27       | Terminal ileum    |
| 16          | M   | 31       | Right-sided       |
| 17          | M   | 42       | Ileocolonic       |  

Ulcerative colitis-active

| Patient No. | Sex | Age (yr) | Disease extension |
|-------------|-----|----------|-------------------|
| 18          | M   | 37       | Ileocolonic       |
| 19          | M   | 45       | Rectosigmoid      |
| 20          | M   | 42       | Rectosigmoid      |
| 21          | M   | 58       | Rectosigmoid      |
| 22          | M   | 28       | Rectosigmoid      |
| 23          | F   | 26       | Rectosigmoid      |
| 24          | M   | 36       | Rectosigmoid      |
| 25          | M   | 27       | Rectosigmoid      |
| 26          | M   | 32       | Rectosigmoid      |
| 27          | F   | 47       | Rectosigmoid      |
| 28          | M   | 33       | Rectosigmoid      |
| 29          | M   | 33       | Rectosigmoid      |
| 30          | M   | 36       | Left-sided        |
| 31          | F   | 44       | Rectosigmoid      |
| 32          | M   | 41       | Rectosigmoid      |
| 33          | M   | 24       | Left-sided        |
| 34          | F   | 58       | Rectosigmoid      |
| 35          | F   | 50       | Rectosigmoid      |
| 36          | M   | 64       | Rectosigmoid      |
| 37          | M   | 48       | Rectosigmoid      |
| 38          | M   | 60       | Pancolitis        |
| 39          | M   | 35       | Pancolitis        |
| 40          | M   | 30       | Rectosigmoid      |
| 41          | M   | 13       | Left-sided        |
| 42          | M   | 52       | Pancolitis        |
| 43          | F   | 38       | Pancolitis        |
| 44          | M   | 17       | Pancolitis        |
| 45          | F   | 26       | Left-sided        |
| 46          | M   | 37       | Pancolitis        |
| 47          | M   | 20       | Rectosigmoid      |
| 48          | M   | 43       | Pancolitis        |
| 49          | F   | 51       | Pancolitis        |
| 50          | M   | 32       | Rectosigmoid      |

Ulcerative colitis-Remittent

| Patient No. | Sex | Age (yr) | Disease extension |
|-------------|-----|----------|-------------------|
| 51          | M   | 8        | Ileocolonic       |
| 52          | M   | 18       | Rectosigmoid      |
| 53          | F   | 35       | Rectosigmoid      |
| 54          | F   | 24       | Rectosigmoid      |
| 55          | M   | 36       | Rectosigmoid      |
| 56          | F   | 35       | Rectosigmoid      |
| 57          | M   | 35       | Pancolitis        |
| 58          | F   | 41       | Pancolitis        |
| 59          | M   | 13       | Rectosigmoid      |
| 60          | F   | 44       | Pancolitis        |
| 61          | F   | 45       | Pancolitis        |
| 62          | M   | 60       | Rectosigmoid      |
| 63          | M   | 23       | Rectosigmoid      |
| 64          | M   | 56       | Left-sided        |

and colon carcinoma occurs in 20%-35% patients with IBD. Compared with sporadic colorectal cancers, such as adenomatous polyposis and hereditary non-polyposis colorectal cancer syndrome, the prognosis of UC-associated colorectal cancer is the worst; the 5-year survival rate of patients is the lowest (<40%) [37]. In our study, the positive rate of FHIT expression was 31.88% ± 20.33%, 22.79% ± 16.16%, 42.14% ± 16.82% in initial, active and remittent phases of UC, and 36.07% ± 19.23% in CD, and 57.05% ± 8.86% in normal colon mucosa. Statistically significant differences in FHIT protein expression were observed between the active and remittent phases of UC, between the active phase of UC and normal colon mucosa, as well as between the remittent phase of UC and normal colon mucosa, and between CD and normal colon mucosa. The severer the inflammation (active phase) is, the more reduction the FHIT protein expression is.

The possible interpretations for these results are as follows. IBD is strongly related to environment, and microsatellite instability in 50% UC patients is enhanced during inflammation. Microsatellites are simple repetitive sequences of DNA that are scattered throughout the genome. These sequences are stably inherited, varying from individual to individual, and have a low alteration rate. Instability within these sequences has been recognized as a marker for genome mutations and DNA repair deficiency. Recently, there have been some reports on detecting microsatellite instability in non-neoplastic settings, including inflammatory mucosa of IBD [39]. Inflammation results in an increase in DNA damage, strengthening the ability of cells to repair the damage before replication [40]. Mutations of oncogene and tumor suppressor gene may be the initiating events in tumourigenesis arising from an inflammatory background, and continuous production of mutations may be required for tumor progression [41]. Patients with IBD are characterized by recurrent acute inflammation of the mucosa, mucosal ulceration, and epithelial necrosis and regeneration. Various kinetic analyses have shown increasing epithelial cell proliferation or cell death in crypts and dysplastic glands in IBD, especially in UC [40, 41]. Active inflammation and regeneration may increase epithelial cell turnover, susceptibility to mutagenesis, and neoplastic transformation [42]. The positive rate of FHIT expression in remission of UC was 42.14% ± 16.82%. The possible theoretical explanation is that the abnormal architecture after active ulceration might impair mucosal function and lead to increased cell turnover. Another possibility is that remission in UC is
only relative with mucosal damage at a subclinical and subhistologic level between the time points of obvious relapse.

Chronic inflammation and epithelial cell damage that characterize IBD result in increased cell proliferation and cell death\(^{[41]}\). At the same time, the accelerated cell turnover predisposes to genetic alterations in mucosa, which is in line with dysplasia and carcinoma in IBD. Nobuyasu Arai\(^{[9]}\) et al. suggested that P53 accumulation and high P21WAF1/CIP1 expression accelerate epithelial cell turnover and may result in an elevated risk of developing dysplasia and carcinoma in patients with IBD.

Chronic inflammation and epithelial damage might predispose to DNA damage in mucosa and accelerate the gene mutation. In the present study, FHIT-protein immunohistochemical expression was absent or reduced in IBD, which might be a precursor from inflammation to carcinoma transformation, suggesting that the alteration of FHIT-protein expression might remain long before any histological morphological change\(^{[10]}\). Skopelitou AS\(^{[42]}\) et al. showed that FHIT protein immunostaining is completely absent or reduced in most H pylori-related chronic gastritis, which may play a role in the development and progression of gastric cancer.

Reduced or absent FHIT protein expression may play a role in accelerating epithelial cell turnover or carcinoma transformation in IBD. Diadenosine triphosphate is first sequestered and eventually hydrolyzed by FHIT to ADP and AMP, the balance between cellular AP3A level and FHIT enzymatic activity may affect cell death or survival. Reduced or absent FHIT protein expression can inhibit the enzymatic activity of FHIT and increase the cellular AP3A level. AP3A can strengthen the transmission of cellular survival signals and accelerate the epithelial cell turnover. It has been suggested that AP4A can also be hydrolyzed by FHIT to ADP and AMP. AP4A is an intracellular regulatory molecule which may regulate the ability of cells to adapt to metabolic stresses such as oxidation and DNA damage. When the function of FHIT protein is diminished, the normal level of AP4A is deviated, which may result in the inability of cells to adapt to environmental stresses and cause genetic damage. At the same time, the ratio of AP3A to AP4A is increased, which can also increase cellular survival\(^{[10,20-23,28,30,32-34]}\).

FHIT protein is involved in the regulation of apoptosis in cell culture systems, which is independent of P53, Bax or Bcl-2 expression and has been considered as an independent mechanism for tumor suppression. FHIT-induced apoptosis comprises signaling processes of FHIT-caspase 8-caspase 9-Bid-PARP, which has two pathways: one is activated by caspase-8, the other involves bypassing mitochondria\(^{[31,32]}\). When FHIT protein is abnormal, apoptosis is disrupted and cellular proliferation is accelerated. FHIT is involved in the regulation of cell cycle and DNA retrieval, FHIT protein can transform damaged DNA into S phase\(^{[44]}\). When FHIT protein expression is reduced or absent, disruption of cell cycle regulation leads to uncontrolled proliferation and formation of tumors.

In conclusion, the high frequency of complete absence and/or reduced immunohistochemical expression of FHIT protein suggests that the FHIT gene might be involved in

---

**Figure 1** FHIT protein expression in normal colonic epithelium (A), ulcerative colitis (B, C), and Crohn’s disease (D) (SP × 400).
most cases of IBD, which might be a precursor from the inflammatory conditions to carcinoma transformation.

ACKNOWLEDGMENTS
We are grateful to Wei-Guo Dong, Bao-Ping Yu, He-Sheng Luo, Jie-Ping Yu (Department of Gastroenterology, Xiangfan No.1 Hospital and Department of Gastroenterology, Renmin Hospital of Wuhan University) for their expert technical assistance.

REFERENCES
1. Dong WG, Liu SP, Yu BP, Wu DF, Luo HS, Yu JP. Ameliorative effects of sodium ferulate on experimental colitis and their mechanisms in rats. *World J Gastroenterol* 2003; 9: 2533-2538.
2. Danese S, Sans M, Fiocchi C. Inflammatory bowel disease: the role of environmental factors. *Autoimmun Rev* 2004; 3: 394-400.
3. Neurath MF, Finotto S, Fuss I, Boirivant M, Galle PR, Strober W. Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question. *Trends Immunol* 2001; 22: 21-26.
4. Brannigan AE, O'Connell PR, Hurley H, O'Neill A, Brady HR, Fitzpatrick JM, Watson RW. Neutrophil apoptosis is delayed in patients with inflammatory bowel disease. *Shock* 2000; 13: 361-366.
5. Dijkstra G, Zandoorij AJ, Koboldt AC, de Jager-Krikken A, Liao J, Ho KL, Yang CS, Yang GY. Inhibition of inflammatory mediators in colonic mucosa of patients with inflammatory bowel disease by N-acetylcysteine. *Appl Immunohistochem Mol Morphol* 2001; 9: 143-149.
6. Imaichi EE, Katsanos KH, Michail MC, Tsianos EV, Aghnantis NJ. Immunohistochemical expression of cyclin D1, cyclin E, p21/waf1 and p27kip1 in inflammatory bowel disease: correlation with other cell-cycle-related proteins (Rb, p53, ki-67 and PCNA) and clinicopathological features. *Int J Colorectal Dis* 2004; 19: 325-333.
7. Otta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Shirvashali Z, Morni M, McCue P, Druck T, Croce CM, Huebner K. The Fhit gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated 13(38) breakpoint, is abnormal in digestive tract cancers. *Cell 1996; 84: 587-597.
8. Nakamura M, Nakamura Y, Yoshimura G, Suzuma Ae, Antoszczyk S, Klupinska G, Nawrot B. cyclooxygenase-2 and redox-sensitive gene expression in intestinal inflammatory conditions to carcinoma transformation. *Int J Catcol Dis* 2001; 26: 49-55.
9. Askari M, Miller G, Vo-Dinh T. Synchronous luminescence: a simple technique for the analysis of hydrolysis activity of the fragile histidine triad protein. *Biotechnology Letters* 2001; 23: 1697-1702.
10. paracelus 1997; 19: 2890-2893.
11. Takeuchi Y, Yoneda M, Kinashi I, Hamid AA, Tsutuma Y, Kusakari T, Fujii S. Loss of Fhit protein expression in high-grade and advanced stage endometrial carcinomas. *Anticancer Res 2003; 23: 2837-2843.
12. Perkarsky V, Zanesi N, Palamaruch A, Huebner K, Croce CM. FHT: from gene discovery to cancer treatment and prevention. *Lancet Oncol* 2002; 3: 748-754.
13. O'Keefe LV, Richards RL. Common chromosomal fragile sites and cancer: focus on FRA16D. *Cancer Lett* 2006; 232: 37-47.
14. Iliopoulos D, Güler G, Han SY, Druck T, Ottery M, McCorkell KA, Huebner K. Roles of Fhit and WWOX fragile genes in cancer. *Cancer Lett 2006; 232: 277-288.*
15. Chang YL, Wu CT, Shih YJ, Lee YC. Roles of Fhit and p53 in Taiwanese surgically treated non-small-cell lung cancers. *Br J Cancer* 2003; 89: 320-326.
16. Yang Q, Nakamura M, Nakamura Y, Yoshimura G, Suzuma T, Uememura T, Shimizu Y, Mori I, Sakurai T, Kakudo K. Two-hit inactivation of FHT by loss of heterozygosity and hypermethylation in breast cancer. *Clin Cancer Res 2002; 8: 2980-2989.*
17. Dumon KR, Ishii H, Vecchione A, Trappaso F, Baldassarre G, Chakrani F, Druck T, Rosato EF, Williams NN, Baffa R, During MJ, Huebner K, Croce CM. Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer. *Cancer Res 2001; 61: 4827-4836.*
18. Wada T, Louhelainen J, Hemminki K, Adlowski J, Wijkström H, Norming U, Borgström E, Hansson J, Steineck G. The prevalence of Loss of heterozygosity in chromosome 3, including FHT, in bladder cancer, using the fluorescent multiplex polymerase chain reaction. *BJU Int* 2001; 87: 867-881.
19. Pavlic K, Kriazican S, Cacev T, Haidzija MP, Radosевич S, Cmrlj I, Levanat C, Kapitanovic S. Aberration of FHT gene is associated with increased tumor proliferation and decreased apoptosis-clinical evidence in lung and head and neck carcinomas. *Mutat Res 2001; 472: 442-453.*
20. Mady HH, Melhem MF. FHT protein expression and its relation to apoptosis, tumor histologic grade and prognosis in colorectal adenocarcinoma: an immunohistochemical and image analysis study. *Clin Exp Metastasis 2002; 19: 351-358.*
21. Rocco A, Schandl L, Chen J, Wang H, Tulassay Z, McNamara D, Malfertheiner P, Ebert MP. Loss of FHT protein expression correlates with disease progression and poor differentiation in gastric cancer. *J Cancer Clin Oncol 2003; 129: 84-88.*
Loss of FHIT expression in gastric mucosa of patients with family histories of gastric cancer and Helicobacter pylori infection. *World J Gastroenterol* 2005; **11**:17-21

35 Vera A, Gunson BK, Ussatoff V, Nightingale P, Candinas D, Radley S, Mayer A, Buckels JA, McMaster P, Neuberger J, Mirza DF. Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. *Transplantation* 2003; **75**:1983-1988

36 Agoff SN, Brentnall TA, Crispin DA, Taylor SL, Raaka S, Haggitt RC, Reed MW, Afonina IA, Rabinovitch PS, Stevens AC, Feng Z, Bronner MP. The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia. *Am J Pathol* 2000; **157**:737-745

37 Giaretti W. Aneuploidy mechanisms in human colorectal preneoplastic lesions and Barrett's esophagus. Is there a role for K-ras and p53 mutations? *Anul Cell Pathol* 1997; **15**:99-117

38 Itzkowitz S. Colon carcinogenesis in inflammatory bowel disease: applying molecular genetics to clinical practice. *J Clin Gastroenterol* 2003; **36**:S70-S84; discussion S70-S84

39 Singer II, Kawka DW, Schloemann S, Tessner T, Riehl T, Stenson WF. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. *Gastroenterology* 1998; **115**:297-306

40 Steinkamp M, Geerling I, Seufferlein T, von Boyen G, Egger B, Grossmann J, Ludwig L, Adler G, Reinshagen M. Glial-derived neurotrophic factor regulates apoptosis in colonic epithelial cells. *Gastroenterology* 2003; **124**:1748-1757

41 Ohd JF, Wikström K, Sjölander A. Leukotrienes induce cell-survival signaling in intestinal epithelial cells. *Gastroenterology* 2000; **119**:1007-1018

42 Skopelitou AS, Mitselou A, Katsanos KH, Alexopoulou V, Tsianos EV. Immunohistochemical expression of Fhit protein in Helicobacter pylori related chronic gastritis, gastric precancerous lesions and gastric carcinoma: correlation with conventional clinicopathologic parameters. *Eur J Gastroenterol Hepatol* 2003; **15**:515-523

43 Stein CK, Glover TW, Palmer JL, Glisson BS. Direct correlation between FRA3B expression and cigarette smoking. *Genes Chromosomes Cancer* 2002; **34**:333-340

44 Guo Z, Vishwanatha JK. Effect of regulated expression of the fragile histidine triad gene on cell cycle and proliferation. *Mol Cell Biochem* 2000; **204**:83-88

S- Editor Wang J  L- Editor Wang XL  E- Editor Liu WF